Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gert Ossenkoppele

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Blood|May 4, 2011
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreJoerg Hasford, Michele Baccarani, Verena Hoffmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99Jakob R Passweg, Aristoteles A N Giagounidis, Mathew Simcock, et al.
British Journal of Haematology|January 28, 2016
CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemiaBas Kersten, Matthijs Valkering, Rolf Wouters, et al.
Haematologica|October 8, 2008
Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registryEsa Jantunen, Carmen Canals, Alessandro Rambaldi, et al.
Trials|May 29, 2020
Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meetingKatharina M Lang, Kathryn L Harrison, Paula R Williamson, et al.
Molecular Cancer Therapeutics|March 29, 2018
IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AMLYelena Kovtun, Paul Noordhuis, Kathleen R Whiteman, et al.
Leukemia|May 18, 2021
SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemiaInge van der Werf, Anna Wojtuszkiewicz, Huilan Yao, et al.
Leukemia|July 17, 2021
Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemiaInge van der Werf, Anna Wojtuszkiewicz, Huilan Yao, et al.
Blood|October 7, 2011
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemiaBob Löwenberg, Petra Muus, Gert Ossenkoppele, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2016
Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib TherapyNoortje Thielen, Johan Richter, Matthias Baldauf, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Blood|May 4, 2011
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreJoerg Hasford, Michele Baccarani, Verena Hoffmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99Jakob R Passweg, Aristoteles A N Giagounidis, Mathew Simcock, et al.
British Journal of Haematology|January 28, 2016
CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemiaBas Kersten, Matthijs Valkering, Rolf Wouters, et al.
Haematologica|October 8, 2008
Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registryEsa Jantunen, Carmen Canals, Alessandro Rambaldi, et al.
Trials|May 29, 2020
Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meetingKatharina M Lang, Kathryn L Harrison, Paula R Williamson, et al.
Molecular Cancer Therapeutics|March 29, 2018
IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AMLYelena Kovtun, Paul Noordhuis, Kathleen R Whiteman, et al.
Leukemia|May 18, 2021
SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemiaInge van der Werf, Anna Wojtuszkiewicz, Huilan Yao, et al.
Leukemia|July 17, 2021
Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemiaInge van der Werf, Anna Wojtuszkiewicz, Huilan Yao, et al.
Blood|October 7, 2011
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemiaBob Löwenberg, Petra Muus, Gert Ossenkoppele, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2016
Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib TherapyNoortje Thielen, Johan Richter, Matthias Baldauf, et al.
Pageof 6